Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Website has been updated a little, reads different and the tabs are smaller. http://www.pilottherapeutics.com/
Pilot Therapeutics adopts new name to match mission:
The long and winding journey of Pilot Therapeutics will go forward with a new name, as officials with the Wake Forest University spinoff rechristen the company as Gene Smart Health.
The new name is meant to better convey the firm's technology in the field of nutrogenomics, or the study of how genetics affect the way human bodies respond to food, said Keith Wakeman, president of Gene Smart.
"'Nutrogenomics' is a great word in the science community, but it's also one that is kind of scary to consumers," Wakeman said. "We wanted a name that conveys what we do, but that is simple enough to work both in business-to-business and business-to-consumer environments."
Gene Smart is one of the early home-grown biotech companies in the Triad, based on research into treatments of chronic inflammatory ailments such as asthma and arthritis by Wake Forest University Professor Floyd "Ski" Chilton.
http://milwaukee.bizjournals.com/triad/stories/2008/04/07/story17.html
Nice! I tried .16 for about a minute and then figured hell nobody is waiting to sell out there at .16 when .15 has been sitting there for months...
Shows what I know...
Just filled 20K shares at .16
Another domain for us to keep track of
I like the sound of that little bit of news.
Good job, if I had some loose funds in my account, I would as well.
Nice! I grabbed a few more!
Interesting developments here:
Wednesday, March 26, 2008
New technology is shared during annual briefing
By Richard Craver
JOURNAL REPORTER
Patti Shugart, the vice president of Carolina Liquid Chemistries, works in a wet lab. The company was one of the first tenants.
The seventh-annual technology briefing yesterday showcased ideas that are new and ancient in scope.
The 10 presenters at the briefing at Salem College showcased a range of products and services, from a permeable-pavement system to a digital method for eliminating paperwork for clinical medical trials.
“These companies are helping to form the foundation of Winston-Salem’s technology community, along with the more than 60 companies that have preceded them in this event,” said Mark Wright, the director for news and media for Wake Forest University Baptist Medical Center.
Pine Hall, founded in 1922, was by far the oldest company at the briefing. Its presentation focused on products that it introduced in January: StormPave and RainPave. The new pavers, which cost about 10 percent more than traditional ones, allow storm water to filter through into the ground rather than becoming runoff.
“It’s really a new twist on an ancient pavement option,” said Ted Corvey, the marketing director for Pine Hall. “The pavers capture the first inch of rain, where most pollutants in storm water tends to collect.
“They also help with reducing erosion and lessening the runoff flow into rivers. They can complement or even replace retention ponds in some instances. And you can walk and drive on them.”
Pilot Therapeutics used the briefing to introduce its new name - GeneSmart Health - and a new focus on health-and-wellness products.
“We feel there is a robust pipeline of opportunities for our research in therapeutics, ingredients and wellness,” said Ross Consaul, the chief executive of GeneSmart. Those include products aimed at preventing and treating allergies, asthma, arthritis, diabetes, eczema, psoriasis and depression.
Carolina Liquid Chemistries Corp. is one of the first two tenants of the Wet Lab Launch Park at Piedmont Triad Research Park. It makes and distributes chemistry re-agents that are used for diagnostic applications at hospitals and private laboratories worldwide.
“Not only is operating out of the Wet Lab saving us in development time, but it’s also helping our customers, such as hospitals, clinics and research labs, provide their services faster, as well,” said Phil Shugart, the president of Carolina Liquid.
Clinical Ink’s marketing pitch to groups doing clinical medical trials is essentially to keep the pen and lose the paper.
The company, founded in 2006, provides customers with proprietary software that allows data entry on customized documents, but with the look and feel of traditional paper data-collection forms. It plans to release version 1.0 of its
eSource solution in June.
“Our product can help make clinical trials more efficient from the very start,” said Doug Pierce, the chief executive of Clinical Ink. “It helps to reduce transcription errors, reduce the delay in transmitting data downstream and provide secure data storage.”
Andrew Filipowski, the founder of Rakote.com, said his goal is to provide a Web site where people can upload and manage their collections, whether comic books, baseball cards, stamps or other memorabilia. The Web site also will serve as a clearinghouse for buying, selling and trading collectibles.
“Collecting is inherently an egotistical hobby - mine is bigger and better than yours,” said Filipowski, a self-described comic-book geek, with more than 10,100 in his collection. He also is the son of prolific entrepreneur Andrew “Flip” Filipowski.
The younger Filipowski said that collecting has been “typically chaotic, disorganized and outdated. With the growth in social media sites, the timing is right for cataloging and posting collections to stimulate the debate.
“It also will help collectors to better assess what issues they are missing and help fill in the gaps,” he said.
Other presenters at the briefing were the Center for Biomolecular Imaging at Wake Forest University Health Sciences, Knowledge2Work, PureLux, Spevco and the Wet Lab Launch Pad.
■ Richard Craver can be reached at 727-7376 or at rcraver@wsjournal.com.
http://www.journalnow.com/servlet/Satellite?pagename=WSJ/MGArticle/WSJ_BasicArticle&c=MGArticle&cid=1173355093365
Figured being the Holiday's I post a Christmas Tree. Figure this stock will be a nice present @ some point in the near future.
impatient or needy for cash selling, no other reason to sell.
Cheapies again...
lol- did the same earlier.
Was enough for me to check the homepage for any updates Nada for now.
Had a bid out for 5300 shares at .20 for a few weeks. Got filled today.
I had a bid out on that @ .20 for a few days w/o a fill. Should have known the day I didn't have a fill out for it would be the day the shoe drops.
Only got a partial at .15, still waiting for more myself...
Grabbed 10K .15 shares on that dump - someone got impatient, anymore?
Got a small order in at .24 it just got skipped over...
Looks like someone was only in this hoping for a quick flip on a PR "to come" - thus the bid whack .25 .23 from SBSH retail MM. Flippers shouldn't buy this stock, it's more of a position trade.
Relaunch of the company by EOY.. Sounds good to me..
Very interesting Thanks Steve!
But Wakeman said the process has been aided rather than hindered by Pilot's existing investors and creditors.
"They see what we see, and that is a technology and IP portfolio that is outstanding," Wakeman said. "A lot of stakeholders believe very much in the future of the company, and that has allowed us to get into a position where we can concentrate on moving forward."
The first step will be raising a seed round of funding to pay for the final development work and introduction of Pilot's first new products. Much of that work was completed before the company went out of business the first time, but Wakeman declined to say how much he though Pilot would need to raise to finish the job.
Pilot has opened an office on Fourth Street in Winston-Salem. Wakeman hopes to have the money raised to relaunch the company by the end of the year and to have products on the market by the end of 2008.
There's also this write up:
http://phoenix.bizjournals.com/phoenix/othercities/triad/stories/2007/10/22/story9.html?b=1193025600%5E1536635
Pilot Therapeutics, a once-bright star in the Triad's biotech industry that went out of business after moving to South Carolina in 2002, has named a new executive team.
Both Ross Consaul, Pilot's new CEO, and Keith Wakeman, now president, have extensive backgrounds in product development and research that should help Pilot turn its solid base of technology in the field of anti-inflammatory nutraceuticals and medical foods into products, according to Floyd "Ski" Chilton, a Wake Forest professor who founded the company and spun it off from the university in 1999. He is now its chief technology officer.
"Pilot has always had promising technology and patents in the food, medical food and dietary supplement areas with over 60 issued and pending patents," Chilton said.
Consaul and Wakeman "will unlock the potential to rapidly move our world class technologies and IP to the marketplace," he added.
That technology was quite alluring to South Carolina in 2002, when it offered the company $17 million in incentives to move its operations and its 14 employees there. The capital markets for biotech were still bone-dry after 9/11, though, and the company couldn't raise enough money to keep operating past the end of 2003.
The company lay dormant until earlier this year, when Chilton and Scott Derks, a former official with the South Carolina Department of Commerce, reconstituted a board of directors following the publication of two successful books by Chilton, which reinvigorated interest in Pilot's technology.
Derks served as president of the company during that effort. He will continue with the company as chief operating officer.
Wakeman said it has proven challenging to work through the legal and financial issues associated with reviving a failed company. Among the steps taken so far has been de-listing Pilot as a public company, so detailed financial data was not available.
But Wakeman said the process has been aided rather than hindered by Pilot's existing investors and creditors.
"They see what we see, and that is a technology and IP portfolio that is outstanding," Wakeman said. "A lot of stakeholders believe very much in the future of the company, and that has allowed us to get into a position where we can concentrate on moving forward."
The first step will be raising a seed round of funding to pay for the final development work and introduction of Pilot's first new products. Much of that work was completed before the company went out of business the first time, but Wakeman declined to say how much he though Pilot would need to raise to finish the job.
Pilot has opened an office on Fourth Street in Winston-Salem. Wakeman hopes to have the money raised to relaunch the company by the end of the year and to have products on the market by the end of 2008.
Pilot Therapeutics
CEO: Ross Consaul
Address: 635 W. Fourth St., Winston-Salem 27101
Phone: (336) 793-7018
Reach Matt Evans at (336) 370-2916 or mlevans@bizjournals.com
It has been brought to my attention that Pilot's new management team has been PR'd.
Very Nice!
http://www.forbes.com/prnewswire/feeds/prnewswire/2007/10/19/prnewswire200710191115PR_NEWS_USPR_____CLF044.html
"where we go from here..." That's pretty insulting considering that team.
Would like to know if they are going to PR the new management team and where we go from here...
I did a few times, and got a responses every time, why the need to email?
Emailed these guys today using the email address listed on the website, has anyone else tried to make contact?
From the get go, Pilot Therapeutics had difficulties in setting up distribution channels. They had the product, but didn't have the funding to get it out to the masses. These guys look like they have the answer to that problem Not to mention, they obviously have the financial wherewithal to put it all together.
This part is awesome:
“Collectively, Ross and Keith have created new businesses generating nearly $3 billion revenue and bring tremendous experience in health and nutrition. We are delighted to welcome them to our team,” said Chilton.
Somebody knew something... He sure did not get much though...
hey thanks, I just noticed that post has the same date the News release does on their website: http://www.pilottherapeutics.com/11.html - perhaps the webmaster bidded lol.
Pilot's first medical food product is a proprietary fatty acid combination for the dietary management of allergies and asthma. This product was developed and tested by Pilot in five clinical trials to validate safety and efficacy and licensed to Efficas, a Colorado-based consumer focused health-science and technology company (http://www.efficas.com).
Might I just once again commend this post, quite a fine eye you have there good Sir!
Close up Chart of the last run, thin is an understatemnet...
Sounds even more interesting now...
Last bit of PR here "Wake Forest University Release"
Colorado Company to Sell Medical Food Products Based on Wake Forest Discovery
WINSTON–SALEM, N.C. – A Colorado–based company is launching a line of “medical- food” products for the dietary management of asthma, eczema and other allergic conditions based on discoveries by Floyd H. “Ski” Chilton, Ph.D., of Wake Forest University Health Sciences (WFUHS).
Chilton’s discoveries originally led to the founding of a company called Pilot Therapeutics. Now Pilot Therapeutics and WFUHS have licensed rights to the technology to Efficas Inc. of Boulder, Colo., to allow Efficas to produce and market the therapeutic products, said Michael A. Batalia, Ph.D., director of the Office of Technology Asset Management at Wake Forest.
The Efficas™ Care products are aimed at three health conditions: asthma, eczema and allergy. The Efficas Care line is now available for online purchase.
Research by Chilton, professor of physiology and pharmacology at Wake Forest University School of Medicine, focuses on the role that diet or medical foods play in human disease. As the founder of Pilot Therapeutics, he developed an over-the-counter medical food designed to reduce the production of leukotrienes, substances known to play a significant role in asthma and allergy attacks.
“Through our research and clinical trials, we have learned that allergic individuals have a unique dietary need for two fatty acids, GLA (gamma-linolenic acid) and EPA (eicosapentaenoic acid),” Chilton said. “Our studies also show that increased consumption of these nutrients can inhibit leukotriene production in patients.”
The new products contain a patented formula of marine oil and botanical oil (borage seed oil) that contains the optimal amount and ratio of GLA and EPA.
“The new licensing arrangement between Efficas, WFUHS and Pilot Therapeutics will allow both companies to advance new technology,” Batalia said. “Efficas is a well-funded health science and technology development company with the resources to market these new products, and Pilot Therapeutics now can move on to other product developments.”
Besides founding Pilot Therapeutics, Chilton is also director of a WFUHS research program studying dietary supplements, one of five in the country. The program is supported by a $7.5 million grant from the National Center for Complementary and Alternative Medicine and the Office of Dietary Supplements.
The Wake Forest program is a partnership with Brigham and Women’s Hospital in Boston and is known as the Wake Forest and Brigham and Women’s Program for Botanical Lipids. Botanicals are plant-based dietary ingredients. One of the four main research projects focuses on how borage, marine and echium oils reduce inflammatory messengers that cause diseases such as asthma and arthritis. (Echium oil is a natural vegetable oil rich in short-chain omega-3 polyunsaturated fatty acids that are converted by humans to the fat equivalent of fish oil.)
Efficas, Inc. is a Boulder-based health science and technology development company “committed to developing science-based products for the nutritional management of the immune system both for humans and pets,” according to a company news release.
Efficas has received funding from Life Science Partners BioVentures, Burrill and Company, Great Spirit Ventures, Unilever Technology Ventures, JP Morgan Bay Area Equity Fund and Prolog Ventures
“Immune-related conditions affect millions of people and we believe leukotriene-inhibiting technology holds great promise for improved quality of life for these individuals,“ said Mark Braman, chief executive officer of Efficas.
“Marketing first via the Web allows us to efficiently reach out to the millions of proactive consumers who are seeking information and alternative treatments online,” Braman said. “We will follow with specialty and natural retail distribution, then mass retail distribution to make our products more easily accessible to the broader population.”
Media Contacts: Robert Conn, rconn@wfubmc.edu, Shannon Koontz, shkoontz@wfubmc.edu, or Karen Richardson, krchrdsn@wfubmc.edu, at (336) 716-4587.
Wake Forest University Baptist Medical Center is an academic health system comprised of North Carolina Baptist Hospital and Wake Forest University Health Sciences, which operates the university’s School of Medicine and its other related enterprises including the Piedmont Triad Research Park. The Medical School is ranked 4th in the Southeastern United States in revenues from its licensed intellectual property.
yep...move back to dollar land :)
Bring on the press releases ~Rig
Interesting chart...you can easily see when the stock announced they were coming out of dormancy. Now lets see if this guys can get us back to the earlier PPS levels
Same here...seems worth having at least a few.
Joined you guys.
Joined you guys.
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
724
|
Created
|
11/14/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |